PrediSurge Achieves €6.5 Million in Series A Funding

Oct 19, 2023 | Press

PrediSurge Achieves €6.5 Million in Series A Funding to Propel Cutting-Edge Digital Twin Technology Across the Cardiovascular Landscape


[September, 2023] — PrediSurge, French software company in the field of cardiovascular digital twin, is thrilled to announce the successful closure of its Series A funding round, securing €6.5 million including €4 million in capital. This significant investment has been spearheaded by the operating Italian Venture Capital LIFTT S.p.a, the European Innovation Council (EIC) Fund, with the remarkable support of Saint Victor Capital, UI Investissement – Metropoles Innovations, and Crédit Agricole LHL Capital Innovation.  


This Series A funding follows PrediSurge’s Seed Round in 2020, which raised a substantial €1.5 million, further highlighting the confidence investors place in the company’s groundbreaking technology.  


Since 2017, PrediSurge develops predictive software solutions for cardiovascular interventions treating vascular and structural heart diseases. PrediSurge aims to empower medical professionals and Medtech companies with advanced digital twin technology, enabling them to enhance intervention strategies and fine-tune their medical device designs for optimal outcomes.  

In pursuit of this vision, PrediSurge has developed PlanOpTM, a CE-marked software that utilizes pre-operative imaging to create numerical models simulating the biomechanical behavior of arteries and valves, generating patient-specific digital twins.  


Following different prices and selection (Prix PÉPITE, Concours Docteurs Entrepreneurs, Concours i-Lab 2018, EIC Accelerator laureat), one more time the collective efforts and dedication of the PrediSurge team have been rewarded by these esteemed stakeholders who have embraced and supported company’s mission to enhance the safety and efficiency of minimally invasive cardiovascular procedures 


Among a distinguished cohort of participants, Predisurge is glad to have been selected for this prestigious and challenging EIC Accelerator program. This recognition is the tangible evidence of the disruptive nature and maturity of PrediSurge’s technology. Beyond the financial aspect, this investment underscores the growing confidence of both investors and customers in the company’s ability to drive innovation and create meaningful advancements in the field of cardiovascular care. 


This significant Series A investment is set to drive PrediSurge’s growth in three pivotal areas. Foremost among these objectives is the expansion of the company’s international presence and extend its track record of sales success to leading cardiovascular device manufacturers worldwide. This sales expansion aligns with the goal of making PlanOpTM and digital twin technology accessible to a broader audience of medical professionals, with the ultimate aim of positively impacting patient outcomes. Secondly, to meet the increasing demand for their innovative solutions, PrediSurge will dedicate efforts to industrialize PlanOpTM platform and associated processes. This strategic move is essential for enabling a smooth scale-up and widespread adoption of PrediSurge current and future products. Lastly, with the infusion of fresh capital, PrediSurge is set to elevate its existing product, broaden its capabilities, and explore new segments within the vascular and structural heart domains. This ambitious R&D initiative is designed to further solidify PrediSurge’s position as a leader in cardiovascular digital twin technology.

Francesca Mongardi, Project Manager of LIFTT S.p.a. commented “Investing in PrediSurge aligns with our belief in the transformative power of digital twin technology in the healthcare sector. By enabling accurate simulations, and personalized treatment strategies, PrediSurge’s solutions have the potential to significantly enhance the safety and efficiency of minimally invasive cardiovascular procedures. Their software PlanOpTM, leverages pre-operative imaging to create mathematical-numerical models simulating the biomechanical behavior of patient’s body. These patient-specific digital twins hold the potential to transform cardiovascular interventions, empowering medical professionals and Medtech companies with pre-operative support and prediction of post-operative complications”. 

Bruno Virieux, CEO of PrediSurge, said “Fundraising goes beyond meeting financial needs; it involves strategically aligning with partners who not only share our vision but also enhance our mission to revolutionize cardiovascular care. By leveraging our pioneering blend of Digital Twin and Artificial Intelligence technologies, we are, through this fundraising, well on our way to shaping the future of the cardiovascular field.” 


Cécile Thébault, Investment Director of UI Investment remarked « We have been able to measure the remarquable progress made in recent months in PrediSurge structuring and business strategy. We are very happy to participate to this new step of development aiming at confirming PrediSurge technological solutions leadership on the cardiovascular digital twin markets. » 


Cédric Rolland, Crédit Agricole LHL Capital Innovation commented “Based in Saint-Etienne, PrediSurge developed a powerful software solution targeted towards cardiovascular interventions. We strongly believe that this technology will transform the medical approach and provide benefits for the patients in the future. Crédit Agricole is thrilled to engage with PrediSurge through this fundraising which will allow the company to reach its full potential”. 

“Since 2017, Xavier VALERIO has actively supported PrediSurge, founding SV Capital in 2020 with doctors and entrepreneurs to invest 600K€ through convertible bonds. SV Capital, bolstered by new healthcare professionals, has increased its investment, demonstrating the cardiovascular community’s interest in the PrediSurge project. In total, SV Capital has contributed over 1M€ to PrediSurge, reaffirming its confidence in this promising startup set to revolutionize the management of cardiovascular diseases with the digital twin technique.” 


Svetoslava Georgieva, Chair of the EIC Fund Board, said: “We are pleased to be among investors backing Predisurge in its growth path through the Series A funding round. We see great potential in the company and their innovation transforming the cardiovascular interventions. Our investment will provide them with the means to develop and scale their businesses in Europe.” 


About the EIC Fund 
The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance.  

The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialisation of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding.  

The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries. 

Other news

PrediSurge at VEITH Symposium 2023

PrediSurge at VEITH Symposium 2023

𝗚𝗼𝘁 𝗽𝗹𝗮𝗻𝘀 𝗳𝗼𝗿 𝗩𝗘𝗜𝗧𝗛 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟬𝟮𝟯? 𝗪𝗲 𝘀𝘂𝗿𝗲 𝗱𝗼! 🔹cutting edge discussions about the future of cardiovascular care;🔹AR visualization of clinical case;🔹interesting product demos ... and much more. Our team is waiting for you at #booth215 to answer all your questions!...

lire plus
PrediSurge at PVI 2023

PrediSurge at PVI 2023

📍 Venue: Carrousel du Louvre🔍 Booth: 24 We are excited to announce that Predisurge will attend the Paris Vascular Insight from 8th to 10th November! 🗓️ Come and meet our team at #booth24 and discover our latest developments in predictive simulation...

lire plus